Decision Resources, Inc., June 2006, Pages: 28
and Personalized Medicine
Europe
Japan
- Outlook
The Public’s Perspective
Pricing and Reimbursement
Development of Diagnostic Tests
List of Figures & Tables
Figure 1 Application of Pharmacogenomics and Effects
Global Industry Analysts, Inc., Oct 2010, Pages: 659
This report analyzes the worldwide markets for Molecular Diagnostics in US$ million by the following segments: Infectious Disease Testing, Pharmacogenomics, and Cancer Screening.
The report
Decision Resources, Inc., March 2011, Pages: 22
? Are the opportunities provided by use of validated biomarkers worth the resource-intensive validation and qualification processes?
- Pharmacogenomic biomarker data are only voluntarily submitted to the FDA in drug
Decision Resources, Inc., Nov 2006, Pages: 31
on Blockbusters
Chronology of Events
The Clincher: The Arrival of Pharmacogenomic Blockbusters
Outlook
Addendum—Global Blockbuster Drugs, 2005
Tables
1. Global Products Achieving Blockbuster Status
RNCOS E-Services Private Limited, March 2011, Pages: 70
.
As per our new research report “Global Bioinformatics Market Outlook”, the market for bioinformatics will surge at a CAGR of nearly 26% during 2011-2013 to reach a value of around US$ 6.2 Billion by 2013
Renub Research, Feb 2011, Pages: 60
. From technology point of view segments like Molecular Diagnostics, Biochips, Pharmacogenomics, SNP Genotyping, Pharmacogenetics, Point of Care Testing, Genetic Screening and Pharmacoproteomics markets
Arrowhead Publishers, May 2010, Pages: 261
’s Personalized Medicine 2010 include:
- Case studies of leading pharmacogenomic products
- Analysis of the personalized medicine market, including seven major market sales forecasts to 2016
- Regulatory
Business Insights, April 2008, Pages: 265
in vitro diagnostics market
Outlook for the diagnostic biomarkers market
Cancer: immunoassays and microarrays
Cardiovascular disease: immunoassays
Infection biomarkers
Predisposition and pharmacogenomic
Decision Resources, Inc., Nov 2009, Pages: 28
of these tests? What are the different ways in which these tests marketed?
- Europe has identified more pharmacogenomic markers than the United States or Japan. For how many drugs does the EMEA support
Bizacumen Inc., Nov 2009, Pages: 488
pharmaceutical R&D. These technologies include bioanalytical instruments, genomics, pharmacogenomics, combinatorial chemistry, biochip, proteomics, bioinformatics and high throughput screening (HTS). Use
Business Insights, Oct 2009, Pages: 141
and identifies the most exciting new technologies and trends, ranging from body imaging and cytology to molecular diagnostics and pharmacogenomics. The report also identifies the key challenges facing innovative
Decision Resources, Inc., Dec 2007, Pages: 31
is in fact fierce, and the efficacy bar for current AD therapies is low; market penetration will therefore hinge on safety profiles. In that regard, the use of pharmacogenomics may cause AD patients
Decision Resources, Inc., Aug 2006, Pages: 31
Spectrum Expert Commentary: FDA Establishes New Processes:
Pharmacogenomic Data Submissions and a Drug-Test Codevelopment Pathway
Outlook
Tables:
1 Financial Position of Key PGx Leaders, FY05
2 Select
Takeda Pacific, Feb 2010, Pages: 144
, applications, M&As, alliances, tools & technologies, products and R&D services. This report provides a detailed outlook of the market for biomarkers and related genomic, proteomic, or other tests used in drug R
Global Industry Analysts, Inc., Sep 2008, Pages: 321
The global outlook series on Biotechnology provides a collection of statistical anecdotes, market briefs, and concise summaries of research findings. The report offers a bird’s eye view
Venture Planning Group, Jan 2012, Pages: 85
. Decentralization
g. Health Care Expenditures
h. Physician Population
i. Hospital Indicators
4. Outlook for the In Vitro Diagnostics Market
a. Overview
b. Molecular Diagnostics
c. Monoclonal Antibodies
d
Decision Resources, Inc., Nov 2008, Pages: 26
for commercialization?
Scope:
-NGS in context: data and trends that pose current challenges to R&D; pharmacogenomics; benefits of NGS.
-Personalized medicine: opportunities, challenges, trends.
-Strategic
Decision Resources, Inc., March 2007, Pages: 28
; and pharmacogenomic testing, genetic testing, predictive testing, and companion diagnostics.
Why does scope for greater innovation and greater sales potential lie in the third phase? According to industry experts
TriMark Publications, July 2011, Pages: 201
Laboratories
5.13 New Technologies and Products under Development
5.13.1 OncoMethylome
5.14 Pharmacogenomics Tests
5.14.1 MGMT Methylation Assay
5.14.2 Other Pharmacogenomic Opportunities
5.15 Recurrence
